Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/187444
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gómez Bravo, Miguel Ángel | - |
dc.contributor.author | Prieto Castillo, Martín | - |
dc.contributor.author | Navasa, Miquel | - |
dc.contributor.author | Sánchez Antolín, Gloria | - |
dc.contributor.author | Lladó Garriga, Laura | - |
dc.contributor.author | Otero, Alejandra | - |
dc.contributor.author | Serrano, Trinidad | - |
dc.contributor.author | Jiménez Romero, Carlos | - |
dc.contributor.author | García González, Miguel | - |
dc.contributor.author | Valdivieso, Andrés | - |
dc.contributor.author | González Diéguez, María Luisa | - |
dc.contributor.author | Mata, Manuel de la | - |
dc.contributor.author | Pons, José A. | - |
dc.contributor.author | Salcedo, Magdalena | - |
dc.contributor.author | Rodrigo, Juan M. | - |
dc.contributor.author | Cuervas Mons, Valentín | - |
dc.contributor.author | González Rodríguez, Antonio | - |
dc.contributor.author | Caralt, Mireia | - |
dc.contributor.author | Pardo, Fernando | - |
dc.contributor.author | Varo Pérez, Evaristo | - |
dc.contributor.author | Crespo, Gonzalo | - |
dc.contributor.author | Rubin, Ángel | - |
dc.contributor.author | Guilera Sardà, Magda | - |
dc.contributor.author | Aldea, Anna | - |
dc.contributor.author | Santoyo, Julio | - |
dc.date.accessioned | 2022-07-07T12:41:42Z | - |
dc.date.available | 2022-07-07T12:41:42Z | - |
dc.date.issued | 2022-01-01 | - |
dc.identifier.issn | 1130-0108 | - |
dc.identifier.uri | http://hdl.handle.net/2445/187444 | - |
dc.description.abstract | Background and aim: reduction in calcineurin inhibitor levels is considered crucial to decrease the incidence of kidney dysfunction in liver transplant (LT) recipients. The aim of this study was to evaluate the safety and impact of everolimus plus reduced tacrolimus (EVR + rTAC) vs. mycophenolate mofetil plus tacrolimus (MMF + TAC) on kidney function in LT recipients from Spain. Methods: the REDUCE study was a 52-week, multicenter, randomized, controlled, open-label, phase 3b study in de novo LT recipients. Eligible patients were randomized (1:1) 28 days post-transplantation to receive EVR + rTAC (TAC levels <_ 5 ng/mL) or to continue with MMF + TAC (TAC levels = 6-10 ng/mL). Mean estimated glomerular filtration rate (eGFR), clinical benefit in renal function, and safety were evaluated. Results: in the EVR + rTAC group (n = 105), eGFR increased from randomization to week 52 (82.2 [28.5] mL/min/1.73 m2 to 86.1 [27.9] mL/min/1.73 m2) whereas it decreased in the MMF + TAC (n = 106) group (88.4 [34.3] mL/min/1.73 m2 to 83.2 [25.2] mL/min/1.73 m2), with significant (p < 0.05) differences in eGFR throughout the study. However, both groups had a similar clinical benefit regarding renal function (improvement in 18.6 % vs. 19.1 %, and stabilization in 81.4 % vs. 80.9 % of patients in the EVR + rTAC vs. MMF + TAC groups, respectively). There were no significant differences in the incidence of acute rejection (5.7 % vs. 3.8 %), deaths (5.7 % vs. 2.8 %), and serious adverse events (51.9 % vs. 44.0 %) between the 2 groups. Conclusion: EVR + rTAC allows a safe reduction in tacrolimus exposure in de novo liver transplant recipients, with a significant improvement in eGFR but without significant differences in renal clinical benefit 1 year after liver transplantation. | - |
dc.format.extent | 8 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Sociedad Española de Patologia Digestiva (SEPD), Arán Ediciones | - |
dc.relation.isformatof | Postprint del document publicat a: https://doi.org/10.17235/reed.2022.8549/2021 | - |
dc.relation.ispartof | Revista Española de Enfermedades Digestivas, 2022 | - |
dc.relation.uri | https://doi.org/10.17235/reed.2022.8549/2021 | - |
dc.rights | (c) Sociedad Española de Patología Digestiva, Arán Ediciones, 2022 | - |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Trasplantament hepàtic | - |
dc.subject.classification | Malalties del ronyó | - |
dc.subject.other | Hepatic transplantation | - |
dc.subject.other | Kidney diseases | - |
dc.title | Everolimus plus minimized tacrolimus on kidney function in liver transplantation: REDUCE, a prospective, randomized controlled study | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/acceptedVersion | - |
dc.date.updated | 2022-07-07T10:52:13Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 35469409 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
07_OR_8549_ing_copia.pdf | 896.09 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.